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Abstract: Preclinical animal models of breast cancer provide the opportunity to identify chemopreventive drugs with single-agent
activity as well as effective multi-modality regimens for primary as well as secondary prevention in high-risk persons. Our group has
used the 7,12-dimethylbenz(a)anthracene (DMBA) mouse model of carcinogen-induced breast cancer to explore the clinical potential
of two tyrosine kinase inhibitors and a nucleoside analog as chemopreventive agents. All three agents exhibited promising preclinical
activity both as monotherapy and as components of combination therapy with the standard chemotherapy drug paclitaxel. The tumors
developing despite chemoprevention were not only small and grew slowly, but they also displayed a uniquely more pro-apoptotic
protein expression profile. Hence, our experimental chemopreventive drugs were capable of preventing the development of aggressive
mammary gland tumors with an apoptosis-resistant protein expression profile.
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1. Introduction
Over 1.5 million women are diagnosed with and over 0.5
million women die of breast cancer each year. Although
breast cancer mortality has declined over the past two
decades, breast cancer remains the leading cause of cancer
deaths in women aged 20 to 59 years [1, 2]. The adverse
impact of breast cancer on quality of life, productivity,
and survival, as well as health care costs, have prompted
intensive research efforts aimed at the identification
of breast cancer prevention methods [3]. Effective
chemoprevention strategies with selective estrogen
receptor modulators (SERMs), such as tamoxifen, and
aromatase inhibitors (AIs), including steroidal inhibitors
such as exemestane, and nonsteroidal inhibitors, such as
anastrozole and letrozole, have been developed to decrease
the risk of both invasive and noninvasive breast cancer [3,
4]. An analysis of 83.399 women at high risk for breast
cancer who received SERMs for primary chemoprevention
showed a 38% reduction in breast cancer incidence [5].
AIs administered as adjuvant therapy after breast surgery
were highly effective in reducing the incidence of breast
cancer recurrence in women who are diagnosed with
breast cancer [6]. In a randomized exemestane study
designed to detect a 65% relative decline in invasive breast

cancer, 4560 eligible postmenopausal women aged 35
or over had at least one of the following risk factors: 60
years or older; Gail 5-year risk score is more than 1.66%
(chances in 100 of invasive breastcancer developing within
5 years); prior atypical ductal or lobular hyperplasia or
lobular carcinoma in situ; or ductal carcinoma in situ
with mastectomy, Exemestane decreased the incidence of
invasive breast cancers [7]. Available chemoprevention
strategies are also related to significant short- and longterm side effects. Guidelines have been developed by
the US Preventive Services Task Force (USPSTF) [8, 9]
and the American Society of Clinical Oncology (ASCO)
[10] regarding the rationale and data-driven, evidencebased use of endocrine therapy for women at high risk
for breast cancer. Precision medicines, as well as targeted
biotherapeutic agents such as Trastuzumab (Herceptin),
offer the opportunity for patient-tailored secondary
prevention of breast cancer [11,12]. The discovery of
additional effective chemopreventive strategies using
chemotherapy drugs, precision medicines, biologics,
and natural compounds is a major area of translational
research emphasis in contemporary oncology [13].
Our recent drug discovery efforts have focused on a
data-driven strategy to identify active chemopreventive
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agents for breast cancer by leveraging an in vivo animal
model for carcinogen-induced breast cancer. The purpose
of the current review is to summarize the salient features
of our studies as well as discuss the insights and lessons
learned from biomarker analyses.
2. The 7,12-dimethylbenz(a)anthracene model of breast
cancer
Mice treated with the chemical carcinogen
7,12-dimethylbenz(a)anthracene
(DMBA)
develop
mammary gland tumors that morphologically resemble
human myoepithelial carcinomas and myoepitheliomas
[14]. Adenosquamous carcinomas and ductal carcinomas
have also been reported in DMBA-treated mice [15].
The polycyclic aromatic hydrocarbons like DMBA
activate the aryl hydrocarbon receptor (AhR), which
activates a signal transduction cascade that leads to
the formation of the mutagenic epoxide of DMBA via
cytochromes P450 enzymes. DNA damage due to this
mutagenic epoxide is the proposed driving mechanism of
malignant transformation in breast tissue [16]. The DMBA
initiates and affects multiple steps of carcinogenesis,
starting from the inhibition of differentiation in the
early stages and followed by cell cycle disruptions such
as upregulation of Cyclin D1 and c-Myc, possibly via
nuclear factor-κB and Wnt pathways [17]. Disruptions of
intracellular members of cell cycle regulation such as PI3K/
mTOR/AKT and PTEN were also seen later in the disease
course similar to luminal type human breast cancers [18].
In a series of studies, we have used the DMBA model of
breast cancer to evaluate the chemopreventive activity of
promising new agents in side by side comparison with
the standard antibreast cancer drug paclitaxel. All control
mice treated with DMBA developed mammary gland
tumors within 16 weeks. The median time for progressionfree survival (in other terms time to tumor development)
was 13 weeks for these mice. The standard breast cancer
drug paclitaxel preventedor slowed down the development
of mammary tumors significantly and more than 25% of
rodents remained tumor-free even after 23 weeks. The
progression-free survival was increased to 16 weeks in the
paclitaxel arm also (Figure 1).
3. Antitumor activity of novel WHI-P131, LFM-A13 and
stampidine molecules in DMBA models of breast cancer
In preclinical models, the phosphoramide derivatives
of nucleoside analogs showed anti-tumor activities and
emerged as potential anticancer drugs [19]. Stampidine is
among these agents and it’s an aryl phosphate derivative of
stavudine. Its clinical activity was first tested as an anti-HIV
agent in preclinical models and also in a phase 1 study[20].
The drug was well-tolerated without dose-limiting
toxicities [20]. Stampidine has been shown to act as an
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epigenetic regulator of gene expression by methylating and
silencing the several oncogenic transcription factors[21].
We tested the chemopreventive activity of stampidine in
the DMBA model. When co-administered with DMBA,
stampidine decreased the number and size of mammary
gland tumors that have developed after the DMBA
challenge. In addition, the combination of stampidine
and paclitaxel synergistically reduced the tumor burden.
Another hypothesis-generating point from our study
was the demonstration of higher proapoptotic and lower
antiapoptotic protein expression in tumors developing in
stampidine-treated mice [22]. These results demonstrated
that stampidine prevents the development of aggressive
breast tumors DMBA challenge. The chemopreventive
potency of stampidine was similar to that of paclitaxel
as well as two potent kinase inhibitors, WHI-P131 (an
inhibitor of HER, Src, and JAK family kinases) [22–25] and
LFM-A13 (an inhibitor of TEC and PLK family kinases)
[26] (Figures 2–4). These findings illustrate the potential
of stampidine as a chemopreventive agent against breast
cancer.
In regards to the two lead kinase inhibitors we tested,
WHI-P131 was active in the DMBA induced cancer
model. The median tumor free-survival was 18 weeks
with WHI-P131 with 20% of mice were tumor in the
18th week of DMBA treatment. This tumor-free survival
was significantly improved compared to the control arm
(P £ 0.001). The antitumor efficacy was similar to that
of paclitaxel (P =0.544) (Figures 2 and 3) [25]. We think
that the combination of WHI-P131 with conventional
chemotherapeutics can further improve the antitumor
efficacy of WHI-P131 as a chemopreventive agent.
The other novel agent we evaluated was LFM-A13
(19). In the DMBA model, LFM-A13 significantly
increased the survival to 40% compared to 15% in the
control arm. The combination of paclitaxel and LFM-A13
further increased the survival rate to 50% in the 25th
week. The tumor incidence and also tumor burden
were significantly reduced in the LFM-A13 group [26].
LFM-A13 prolonged the tumor-free interval by 2 weeks
(15 vs 13 weeks, P = 0.0002) compared to the control arm.
30% of mice treated with LFM-A13 were tumor-free at
20th week demonstrating long-lasting chemoprevention
with the agent. The antitumor efficacy was similar to that
of paclitaxel and WHI-P131 (Figures 2–4).
Notably,
the
tumors
developing
despite
chemoprevention with the kinase inhibitors or stampidine
were not only small and grew slowly, but they also
displayed a uniquely more proapoptotic protein expression
profile. Hence, our experimental chemoprentive drugs
are capable of preventing the development of aggressive
mammary gland tumors with an apoptosis-resistant
protein expression profile.
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Figure 1. Effects of paclitaxel on the proportion of tumor-free survival (a) and macroscopic appearance
and histopathological features (b; H&E X200) of DMBA-induced tumors in the mammary glands of mice.

4. Future perspectives
Although the use of tamoxifen and AI’s for secondary
prevention have significantly reduced the risk of are
recurrence in hormone receptor-positive breast cancer
after standard first-line therapy (5, 27), many high-risk
patient populations (especially those with hormone
receptor-negative breast cancer) experience a recurrence.
Optimizing secondary prevention with drugs used in the
adjuvant and prolonged maintenance therapy settings
may contribute to a clinically meaningful improvement
of survival outcome. Our data in the DMBA model
suggest that stampidine, WHI-P131, and LFM-A13 may
be useful as chemopreventive agents and as components
for secondary chemoprevention protocols. In the DMBA
model, the efficacy of these agents in chemoprevention

was similar to that of paclitaxel which is among the most
effective breast cancer therapies [27]. We are planning to
evaluate their activity in combination with tamoxifen and
AIs for secondary prevention considering the potential
to inhibit different steps of oncogenesis due to different
mechanisms of antitumor action. The enhanced potency
observed when these agents were combined with paclitaxel
is also deserving of further study [22, 25]. LFM-A13 and
WHI-P131 were also tested for activity in MMTV/Neu
transgenic HER-2 positive models of breast cancer [23,
28], so their synergism with trastuzumab is another area
that warrants further research.
As mentioned earlier, the tumors developing
despite chemoprevention with the kinase inhibitors or
stampidine displayed a pro-apoptotic protein expression
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Figure 2. Effects of chemoprevention with paclitaxel, LFM-A13, WHI-P131 and stampidine on proportion tumorfree survive in DMBA-challenged mice.

2.5

**** P < 0.0001 vs DMBA
*** P < 0.001 vs DMBA
* P < 0.05 vs DMBA

Tumor s ize (cm3 )

2.0

*

1.5

****

1.0

****

***

WHI-P 131

Stampidine

0.5

0.0

DMBA

Paclita xe l

LFM-A13

Figure 3. Effects of chemoprevention with paclitaxel, LFM-A13, WHI-P131 and stampidine on the tumor size in
DMBA-challenged mice.

profile, which was different from the protein expression
profile of aggressive tumors developing in DMBAtreated control mice [22]. Hence, our experimental
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chemopreventive drugs are capable of preventing the
development of aggressive mammary gland tumors with
an apoptosis-resistant protein expression profile. It is
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Figure 4. Effects of chemoprevention with paclitaxel, LFM-A13, WHI-P131 and stampidine on total tumor load
in DMBA-challenged mice.

our working hypothesis that recurrent tumors emerging
after chemoprevention with these chemopreventive drugs
will, therefore, be substantially more sensitive to available
salvage chemotherapy regimens in standard second-line
settings. This should contribute to an improved treatment
and survival outcome after recurrence.
One of the most important properties of these
rationally designed agents is their tolerability which
increases their potential to be used in the combinations.
All three agents were well tolerated without dose-limiting
hematologic, renal and hepatic toxicities in multiple
animal studies [26, 28, 29]. Stampidine did not cause any
dose-limiting toxicities in a phase 1 study of thirty HIV
patients [20]. However, LFM-A13 and WHI-P131have
not been evaluated in human subjects and all three drugs
remain to be evaluated to breast cancer patients.
In summary, stampidine, LFM-A13, and WHI-P131

showed potent chemopreventive activity by reducing the
development and number of breast tumors and improving
the tumor-free survival outcome in breast cancer animal
models. Further models and studies testing the synergism
of these agents with another chemopreventive agent like
tamoxifen and AI’s and also the use of these agents for
primary chemoprevention in women at high risk for breast
cancer would seem warranted.
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